Acquisition of complement resistance through incorporation of CD55/decay-accelerating factor into viral particles bearing baculovirus GP64. 2010

Yuuki Kaname, and Hideki Tani, and Chikako Kataoka, and Mai Shiokawa, and Shuhei Taguwa, and Takayuki Abe, and Kohji Moriishi, and Taroh Kinoshita, and Yoshiharu Matsuura
Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan.

A major obstacle to gene transduction by viral vectors is inactivation by human complement in vivo. One way to overcome this is to incorporate complement regulatory proteins, such as CD55/decay accelerating factor (DAF), into viral particles. Lentivirus vectors pseudotyped with the baculovirus envelope protein GP64 have been shown to acquire more potent resistance to serum inactivation and longer transgene expression than those pseudotyped with the vesicular stomatitis virus (VSV) envelope protein G. However, the molecular mechanisms underlying resistance to serum inactivation in pseudotype particles bearing the GP64 have not been precisely elucidated. In this study, we generated pseudotype and recombinant VSVs bearing the GP64. Recombinant VSVs generated in human cell lines exhibited the incorporation of human DAF in viral particles and were resistant to serum inactivation, whereas those generated in insect cells exhibited no incorporation of human DAF and were sensitive to complement inactivation. The GP64 and human DAF were detected on the detergent-resistant membrane and were coprecipitated by immunoprecipitation analysis. A pseudotype VSV bearing GP64 produced in human DAF knockdown cells reduced resistance to serum inactivation. In contrast, recombinant baculoviruses generated in insect cells expressing human DAF or carrying the human DAF gene exhibited resistance to complement inactivation. These results suggest that the incorporation of human DAF into viral particles by interacting with baculovirus GP64 is involved in the acquisition of resistance to serum inactivation.

UI MeSH Term Description Entries
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003169 Complement Inactivator Proteins Serum proteins that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host. The complement system is tightly regulated by inactivators that accelerate the decay of intermediates and certain cell surface receptors. Complement Cytolysis Inhibiting Proteins,Complement Cytolysis Inhibitor Proteins,Complement Inactivating Proteins,Serum Complement Inactivators,Complement Inactivators, Serum,Inactivating Proteins, Complement,Inactivator Proteins, Complement,Inactivators, Serum Complement,Proteins, Complement Inactivating,Proteins, Complement Inactivator
D006031 Glycosylation The synthetic chemistry reaction or enzymatic reaction of adding carbohydrate or glycosyl groups. GLYCOSYLTRANSFERASES carry out the enzymatic glycosylation reactions. The spontaneous, non-enzymatic attachment of reducing sugars to free amino groups in proteins, lipids, or nucleic acids is called GLYCATION (see MAILLARD REACTION). Protein Glycosylation,Glycosylation, Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012831 Bombyx A genus of silkworm MOTHS in the family Bombycidae of the order LEPIDOPTERA. The family contains a single species, Bombyx mori from the Greek for silkworm + mulberry tree (on which it feeds). A native of Asia, it is sometimes reared in this country. It has long been raised for its SILK and after centuries of domestication it probably does not exist in nature. It is used extensively in experimental GENETICS. (From Borror et al., An Introduction to the Study of Insects, 4th ed, p519) Bombyx mori,Silkmoths,Silkworms,Silkmoth,Silkworm,Bombyx morus,Bombyxs,mori, Bombyx
D014721 Vesicular stomatitis Indiana virus The type species of VESICULOVIRUS causing a disease symptomatically similar to FOOT-AND-MOUTH DISEASE in cattle, horses, and pigs. It may be transmitted to other species including humans, where it causes influenza-like symptoms. Vesicular stomatitis-Indiana virus
D014760 Viral Fusion Proteins Proteins, usually glycoproteins, found in the viral envelopes of a variety of viruses. They promote cell membrane fusion and thereby may function in the uptake of the virus by cells. Fusion Proteins, Viral,Viral Fusion Glycoproteins,F Protein (Sendai Virus),F Protein Measles Virus,F Protein Newcastle Disease Virus,F Protein SV,F-Glycoprotein SV,F1 Polypeptide (Paramyxovirus),Fusion Glycoprotein, Viral,Fusion VP1 Protein,Glycoprotein, Viral Fusion,Measles Fusion Protein,Mumps Virus Fusion Protein,Paramyxovirus Fusion Protein,Sendai Virus Fusion Protein,Viral Fusion-GP,Virus Fusion Proteins,Fusion Glycoproteins, Viral,Fusion Protein, Measles,Fusion Protein, Paramyxovirus,Fusion Proteins, Virus,Fusion-GP, Viral,Glycoproteins, Viral Fusion,Proteins, Virus Fusion,VP1 Protein, Fusion,Viral Fusion GP,Viral Fusion Glycoprotein
D014771 Virion The infective system of a virus, composed of the viral genome, a protein core, and a protein coat called a capsid, which may be naked or enclosed in a lipoprotein envelope called the peplos. Virus Particle,Viral Particle,Viral Particles,Particle, Viral,Particle, Virus,Particles, Viral,Particles, Virus,Virions,Virus Particles
D015316 Genetic Therapy Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions. Gene Therapy,Somatic Gene Therapy,DNA Therapy,Gene Therapy, Somatic,Genetic Therapy, Gametic,Genetic Therapy, Somatic,Therapy, DNA,Therapy, Gene,Therapy, Somatic Gene,Gametic Genetic Therapies,Gametic Genetic Therapy,Genetic Therapies,Genetic Therapies, Gametic,Genetic Therapies, Somatic,Somatic Genetic Therapies,Somatic Genetic Therapy,Therapies, Gametic Genetic,Therapies, Genetic,Therapies, Somatic Genetic,Therapy, Gametic Genetic,Therapy, Genetic,Therapy, Somatic Genetic

Related Publications

Yuuki Kaname, and Hideki Tani, and Chikako Kataoka, and Mai Shiokawa, and Shuhei Taguwa, and Takayuki Abe, and Kohji Moriishi, and Taroh Kinoshita, and Yoshiharu Matsuura
May 2001, Nature biotechnology,
Yuuki Kaname, and Hideki Tani, and Chikako Kataoka, and Mai Shiokawa, and Shuhei Taguwa, and Takayuki Abe, and Kohji Moriishi, and Taroh Kinoshita, and Yoshiharu Matsuura
August 2006, Cancer immunology, immunotherapy : CII,
Yuuki Kaname, and Hideki Tani, and Chikako Kataoka, and Mai Shiokawa, and Shuhei Taguwa, and Takayuki Abe, and Kohji Moriishi, and Taroh Kinoshita, and Yoshiharu Matsuura
January 1992, Current topics in microbiology and immunology,
Yuuki Kaname, and Hideki Tani, and Chikako Kataoka, and Mai Shiokawa, and Shuhei Taguwa, and Takayuki Abe, and Kohji Moriishi, and Taroh Kinoshita, and Yoshiharu Matsuura
November 1999, Nihon rinsho. Japanese journal of clinical medicine,
Yuuki Kaname, and Hideki Tani, and Chikako Kataoka, and Mai Shiokawa, and Shuhei Taguwa, and Takayuki Abe, and Kohji Moriishi, and Taroh Kinoshita, and Yoshiharu Matsuura
August 1991, Immunology letters,
Yuuki Kaname, and Hideki Tani, and Chikako Kataoka, and Mai Shiokawa, and Shuhei Taguwa, and Takayuki Abe, and Kohji Moriishi, and Taroh Kinoshita, and Yoshiharu Matsuura
April 1998, European journal of immunology,
Yuuki Kaname, and Hideki Tani, and Chikako Kataoka, and Mai Shiokawa, and Shuhei Taguwa, and Takayuki Abe, and Kohji Moriishi, and Taroh Kinoshita, and Yoshiharu Matsuura
April 2005, Molecular therapy : the journal of the American Society of Gene Therapy,
Yuuki Kaname, and Hideki Tani, and Chikako Kataoka, and Mai Shiokawa, and Shuhei Taguwa, and Takayuki Abe, and Kohji Moriishi, and Taroh Kinoshita, and Yoshiharu Matsuura
July 1993, Journal of immunology (Baltimore, Md. : 1950),
Yuuki Kaname, and Hideki Tani, and Chikako Kataoka, and Mai Shiokawa, and Shuhei Taguwa, and Takayuki Abe, and Kohji Moriishi, and Taroh Kinoshita, and Yoshiharu Matsuura
January 2005, The Journal of biological chemistry,
Yuuki Kaname, and Hideki Tani, and Chikako Kataoka, and Mai Shiokawa, and Shuhei Taguwa, and Takayuki Abe, and Kohji Moriishi, and Taroh Kinoshita, and Yoshiharu Matsuura
April 1994, The Journal of laboratory and clinical medicine,
Copied contents to your clipboard!